Vulvar and Vaginal Atrophy (VVA) Therapy Market to Make Great Impact in Near Future by 2031
Research Nester published a report titled “Vulvar and Vaginal Atrophy Therapy Market: Global Demand Analysis & Opportunity Outlook 2031” which delivers detailed overview of the global vulvar and vaginal atrophy (VVA) therapy market in terms of market segmentation by symptoms, diagnosis, treatment, end-user, and by region.
Further, for the
in-depth analysis, the report encompasses the industry growth indicators,
restraints, supply and demand risk, along with detailed discussion on current
and future market trends that are associated with the growth of the market.
The global vulvar and vaginal atrophy therapy market is anticipated to grow with a CAGR of ~11% during the forecast
period, i.e., 2022-2031. The market is segmented by treatment into non
hormonal therapy, hormonal therapy, selective estrogen receptor modulators
(SERM), and laser therapy. Out of these, the hormonal
therapy segment is anticipated to garner the largest revenue
by the end of 2031, owing to the increasing number of
cancer cases as the therapy lessens the chances of cancer recurrence. According to the Centers for Disease Control
and Prevention, in 2019, about 1,368 women were diagnosed with vaginal cancer
in the United States. On the other hand, most women are treated with
menopausal hormone therapy (MHT), also known as hormone replacement therapy
(HRT), if they have symptoms related to menopause.
An increasing female
geriatric population, as well as rising lifestyle-related disorders such as
hormonal imbalances, stress, and depression, are expected to drive the growth
of the global vulvar and vaginal atrophy therapy market during the forecast
period.
Geographically, the
global vulvar and vaginal atrophy therapy market is segmented into five regions including North America, Europe,
Asia Pacific, Latin America and Middle East & Africa region. Out of these,
the market in North America is projected to garner the largest share by the end
of 2031. The upsurge in the number of women suffering from pre and postmenopausal
hormonal imbalances, as well as the growing number of cancer cases in the
region, are some of the major factors anticipated to drive the growth of the
market in North America.
Request Report Sample @ https://www.researchnester.com/sample-request-4178
Genitourinary Syndrome
of Menopause (GSM) to Drive the Market Growth
Menopausal genitourinary syndrome affects
approximately 30% to 75% of postmenopausal women and can significantly impair
health, sexual function, and quality of life.
The surge in the number of premenopausal, early menopausal and postmenopausal
cases as well as increasing genitourinary syndrome of menopause (also
known as vulvovaginal atrophy or urogenital trophy) among women globally is driving
the vulvar and vaginal atrophy market.
However,
unreported
cases of genitourinary syndrome of menopause owing to lack of awareness, concerns about vulvar
and vaginal atrophy from cancer combination treatments are expected to operate as key
restraints to the growth of the global vulvar and vaginal atrophy therapy market over the forecast
period.
This report also
provides the existing competitive scenario of some of the key players of the
global vulvar and vaginal atrophy therapy market which includes company profiling of Dare Bioscience, Inc., Almirall,
S.A, Viveve, Inc., Lutronic, Venus Concept, ThermiGen LLC, Alma Lasers, BTL,
Fotona, Therapeutics MD, Inc., and others. The profiling enfolds key
information of the companies which encompasses business overview, products and
services, key financials and recent news and developments. On the whole, the
report depicts detailed overview of the global vulvar and
vaginal atrophy therapy market that will help
industry consultants, equipment manufacturers, existing players searching for
expansion opportunities, new players searching possibilities and other
stakeholders to align their market centric strategies according to the ongoing
and expected trends in the future.
Request Report Sample @ https://www.researchnester.com/sample-request-4178
Comments
Post a Comment